Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: Retrospective population based cohort study

BMJ (Online)

Volumn 346, Issue 7908, 2013, Pages

  Eurich, D T ^a   Simpson, S ^a   Senthilselvan, A ^a   Asche, C V ^b,c   Sandhu Minhas, J K ^a   McAlister, F A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEALTH CARE; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SOCIOECONOMICS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

COMPARATIVE EFFECTIVENESS RESEARCH; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINES AS TOPIC; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PYRAZINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 84878296673     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f2267     Document Type: Article

References (36)

1. National Institute for Health and Clinical Excellence. Quality statement 4: glycaemic control. 2011. http://publications.nice.org.uk/diabetes-in-adults- quality-standard-qs6/quality-statement-4-glycaemic-control.
2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:S1-201.
3. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(suppl 1):S11-3.
4. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428-33.
5. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010;123(3 suppl):S28-37.
6. Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Diabet Med 2013;30:289-99.
7. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012;110:826-33.
8. Ranganath LR. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Clin Pathol 2008;61:401-9. (Pubitemid 351518219)
9. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 2008;117:574-84.
10. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27.
11. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54.
12. Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012;14:596-600.
13. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011;34:369-74.
14. Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy. Clin Ther 2007;29:1784-94. (Pubitemid 47494552)
15. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-10. (Pubitemid 47173656)
16. Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA. Impact of compliance with proton pump inhibitors on NSAID treatment. Am J Manag Care 2009;15:681-8.
17. Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009;31:623-31.
18. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51. (Pubitemid 41384275)
19. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005;22:497-502. (Pubitemid 40516253)
20. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8. (Pubitemid 41071035)
21. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the national death index and Equifax nationwide death search. Am J Epidemiol 1994;140:1016-9. (Pubitemid 24373006)
22. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002;12:462-8.
23. Bowker S, Yasui Y, Veugelers P, Johnson J. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010;53:1631-7.
24. Lipscombe L, Gomes T, Lévesque L, Hux J, Juurlink D, Alter D. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43. (Pubitemid 350254955)
25. Penson DF, Stoddard ML, Pasta DJ, Lubeck DP, Flanders SC, Litwin MS. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol 2001;54:350-8. (Pubitemid 32303458)
26. Huberman M, Langholz B. Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol 1999;150:1340-5.
27. Johns Hopkins University. The Johns Hopkins ACG system. 2012. www.acg.jhsph.org/.
28. Austin PC, Walraven CV. The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care 2011;49:940-7.
29. McAlister F, Eurich D, Majumdar S, Johnson J. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008;10:703-8.
30. Winkelmayer W, Setoguchi S, Levin R, Solomon D. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168:2368-75.
31. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-22.
32. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(suppl 3):57-64.
33. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27.
34. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2012;30:e146-55.
35. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-6.
36. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169-74. (Pubitemid 43166269)